Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProTrials Research has announced the completion of a large Phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.
Subscribe to our email newsletter
This milestone adds to ProTrials’ successful track record in supporting ophthalmology studies investigating new treatments for a broad range of eye conditions, from age-related macular degeneration (AMD) to cataract surgery pain.
In the last three years, ProTrials has conducted four Phase III dry eye studies and multiple Phase III trials across a broad range of therapeutic areas involving over 100 sites and 1000 patients.
Prior to the completion of this trial, the company successfully managed and monitored parallel Phase III AMD treatment studies that resulted in a successful Biologics License Application (BLA) submission.
More than half of the company’s staff has significant ophthalmology experience, and almost 90% have Phase III clinical trial experience.
ProTrials president Inger Arum noted that the company offers experience in many therapeutic areas, but its ability to handle the intricacies required in ophthalmology studies is key to its repeated success in this type of research.
"Sponsors choose ProTrials as a partner because of our excellent track record and the expertise of our senior-level team," Arum added.